{"analyses":[{"ciLowerLimit":"1.080","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.347","groupDescription":"Stratified analysis: Stratified by disease site (visceral vs non-visceral) per randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0090","pValueComment":"1-sided p-value is from exact test.","paramType":"Odds Ratio (OR)","paramValue":"1.594","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.2","upperLimit":"65.9","value":"60.7"},{"groupId":"OG001","lowerLimit":"41.4","upperLimit":"56.9","value":"49.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"171"}],"units":"Participants"}],"description":"The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10mm). PR: \\>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received letrozole 2.5 milligram (mg) orally QD (once daily) combined with palbociclib 125 mg QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG000","title":"Palbociclib Plus Letrozole"},{"description":"Participants received letrozole 2.5 mg orally QD combined with placebo QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG001","title":"Placebo Plus Letrozole"}],"paramType":"NUMBER","populationDescription":"Participants who had measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"From randomization until end of treatment (up to approximately 2.5 years)","title":"Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}